

ASX ANNOUNCEMENT

PeriCoach® granted patent protection in Japan

22nd February 2017 - Brisbane, Australia – Analytica Ltd (ASX: ALT). Analytica has been granted patent protection in Japan (Patent N^o. 6069297) for the PeriCoach® System's unique pelvic floor force sensing technology.

Patents on the PeriCoach force sensors have now issued in China and Japan, with patents pending in US, India, Brazil, Australia, and Europe. Most jurisdictions allow patent protection for 20 years from the original lodgement date.

Japan has enormous market potential for a global licensee with an estimated 15.8 million women aged 15-85+ currently suffering the effects of Urinary Incontinence¹.

It has remained a top priority to ensure that PeriCoach becomes a global product, therefore Analytica has maintained its investment in intellectual protection in major markets around the world. The intellectual property strategy remains to secure protection in key geographies that have ageing populations, with increased awareness of urinary incontinence, and growing demand towards conservative treatment solutions.

Analytica CEO Geoff Daly said – "Patent protection is a long process, often many taking years before patents are issued. We are diligently working behind the scenes to ensure that we get the full benefit from the hard work and innovations of my product development team. Intellectual property rights are always critical in licencing negotiations as it affords the licencing partner freedom to operate in the world's most commercially attractive markets."

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA.



¹ Datamonitor Report DMKC0057793 25/1/2011 Alyssa Klein – Urinary Incontinence Epidemiology.